[Targeting chemotherapy with transferrin-neocarzinostatin conjugate]

Area of Science:

• Biotechnology
• Oncology
• Pharmacology

Context:

• Targeted drug delivery aims to increase therapeutic efficacy and reduce side effects of anticancer agents.
• Transferrin receptors are overexpressed on many cancer cells, making them a promising target for drug delivery.
• Neocarzinostatin (NCS) is a potent anticancer agent with limitations in systemic administration.

Purpose:

• To develop a targeted drug delivery system for anticancer agents using transferrin receptor-mediated endocytosis.
• To conjugate human diferric transferrin with neocarzinostatin (NCS) to create a ligand-drug complex.
• To evaluate the in vitro and in vivo efficacy and toxicity of the transferrin-NCS conjugate.

Summary:

• Human diferric transferrin was conjugated with neocarzinostatin (NCS) via N-succinimidyl 3-(2-pyridyldithio)-propionate.
• The transferrin-NCS conjugate demonstrated effective binding to transferrin receptors and internalization into cancer cells.
• Significant inhibition of M7609 human colorectal cancer cell growth was observed both in vitro and in vivo in nude mice.
• The conjugate exhibited a longer half-disappearance time (55 min) compared to free NCS (7 min), with transient, mild toxicity (decreased red blood cell count).

Impact:

• This transferrin-NCS conjugate serves as a viable model for receptor-mediated ligand-drug complex delivery.
• The findings suggest potential for future clinical applications in targeted cancer therapy.
• The targeted approach may enhance the therapeutic index of potent anticancer agents like NCS.